COPD
Reimbursement: Up to £850 from Screening to Week 56, and £50 per visit thereafter depending on scheduled visits, plus travel expenses.
About This clinical research study
Here at MAC Clinical Research we are conducting a trial to test a potential new treatment for Chronic Obstructive Pulmonary Disease (COPD). COPD is a disease frequently caused by tobacco use, which causes swelling and destruction of the lungs and results in symptoms such as cough, shortness of breath, and sputum production. COPD is generally a progressive disease that gets worse over time and is associated with flare-ups also called exacerbations.
This study is being carried out to evaluate a new study drug compared to placebo as a medicine to treat moderate to very severe COPD associated with elevated blood eosinophils and history of frequent exacerbation. The study drug makes it a potential treatment option for the high unmet need in COPD patients with eosinophilic inflammation and those at risk for exacerbations. The study drug is being developed as an adjunctive maintenance treatment for the prevention of exacerbations in patients with COPD.
Reimbursement: Up to £850 from Screening to Week 56, and £50 per visit thereafter depending on scheduled visits, plus travel expenses.
Clinics
Greater Manchester, Lancashire, South Yorkshire and Teesside
Therapy Area
Chronic Obstructive Pulmonary Disease
Gender and Age
Males and Females aged 40 - 85
A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet and an opportunity to ask the study doctor any questions.
If you contact us, it does not mean you have to decide at that point whether to participate.
If you do decide to participate you are free to withdraw at any time.
The Study Length will last between 56 weeks to approximately 2.5-3 years. There will be 17 out- patients visits (After 56-week treatment period, an optional continuation period may be available with treatment visits every 8 weeks.)
Reimbursement: Up to £850 from Screening to Week 56, and £50 per visit thereafter depending on scheduled visits, plus travel expenses.
Key Inclusion Criteria
- Aged between 40 – 85 years
- Current smoker or ex-smoker with a tobacco history of at least 10 pack-years
- History of moderate to very severe COPD
- Documented history of more than 2 COPD exacerbations requiring treatment with systemic corticosteroids and/or hospitalisation within 52 weeks
- Use of triple (ICS/LABA/LAMA ) therapy for COPD for at least 3 months
Key Exclusion Criteria
- Other pulmonary diseases other than COPD (e.g. active lung infection, bronchiectasis)
- Current diagnosis of asthma
- Signs and/or symptoms of Cor Pulmonale/ right ventricular failure
- History of alcohol or drug abuse within the past year
- History of anaphylaxis to any biologic therapy or vaccine
Other eligibility criteria will apply. Please contact MAC for more information.
If you are eligible you will receive a comprehensive health screen. Your GP will be fully informed of your participation and provided with any information relevant to your healthcare.
ABOUT CLINICAL RESEARCH STUDIES
Clinical research studies are performed as a way of bringing about progress in medicine and research. Clinical research studies make it possible to scientifically assess the properties of a drug, to demonstrate the effectiveness and safety of a treatment or a medical device, or to learn more about a disease and methods to diagnose and monitor it.
If the study is successful, it may be an important step towards developing a promising new treatment.
MAC Clinical Research is conducting a trial to evaluate a potential new treatment for COPD.
If you would like more information, please fill in the form below and we will be in touch…
Alternatively, please call our recruitment team on freephone 0800 633 5507.
Know someone who may be interested in taking part? Share this page here: